NCT00871104

Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis

Evaluation of the Efficacy and Safety of Fosfomycin Plus Imipenem for the Treatment of Methicillin-resistant Staphylococcus Aureus (MRSA) Infective Endocarditis.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Juan A. Arnaiz · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study evaluates the efficacy and safety of fosfomycin and imipenem for the treatment of methicillin-resistant staphyloccocus aureus infective endocarditis in comparison to vancomycin, the standard therapy.

Conditions

• Infective Endocarditis

Interventions

Type	Name	Description
DRUG	Fosfomycin and imipenem	IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
DRUG	Vancomycin	IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg

Timeline

• Start date: 2009-07-01
• Primary completion: 2014-07-01
• Completion: 2015-04-15
• First posted: 2009-03-30
• Last updated: 2018-03-08

Locations

10 sites across 1 country: Spain